Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 4Phase NA 1Phase 1/2 1Phase 1 1

Status

Completed 5

Sponsor Class

INDUSTRY 5OTHER 1NETWORK 1

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 2Plasma cell 1Genitourinary 1Gastrointestinal 1

Conditions

Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Carcinoma 2Rectal Neoplasms 1Prostatic Neoplasms 1Neoplasms by Site 1Neoplasms 1Multiple Myeloma 1

Interventions

Carboplatin 273Paclitaxel 267Gemcitabine 244Bevacizumab 226Cisplatin 218pembrolizumab 214Docetaxel 210Pemetrexed 162Capecitabine 148Fluorouracil 129Oxaliplatin 121Cyclophosphamide 121Nivolumab 112Dexamethasone 100Trastuzumab 89Leucovorin 87Cetuximab 85Rituximab 83Irinotecan 82Injections 81Erlotinib Hydrochloride 70Prednisone 68Doxorubicin 68Temozolomide 67atezolizumab 65Bortezomib 65Ipilimumab 64Fulvestrant 59Radiotherapy 54Drug Therapy 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × L-BLP25 × Clear all
NCT01496131 2018-03-09

Tecemotide (L-BLP25) in Prostate Cancer

EMD Serono

Phase 2 Completed
28 enrolled 9 charts
Genitourinary

Prostatic Neoplasms

NCT01507103 2017-01-13

SPRINT

Merck KGaA, Darmstadt, Germany

Phase 2 Completed
124 enrolled 9 charts
Gastrointestinal

Carcinoma, Neoplasms, Neoplasms by Site, Rectal Neoplasms

NCT01094548 2016-02-22

Study of Tecemotide (L-BLP25) in Subjects With Slowly Progressive Multiple Myeloma With no Symptoms and Who Have Had no Chemotherapy

Merck KGaA, Darmstadt, Germany

Phase 2 Completed
34 enrolled 12 charts
Plasma cell

Multiple Myeloma

NCT00157209 2015-11-18

Phase 2b Randomized Controlled Study of Tecemotide (L-BLP25) for Immunotherapy of NSCLC (Non-Small Cell Lung Cancer)

Merck KGaA, Darmstadt, Germany

Phase 2 Completed
171 enrolled 12 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00157196 2015-08-18

Safety Study of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease

Merck KGaA, Darmstadt, Germany

Phase 2 Completed
22 enrolled 6 charts
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡